Table 4.

Later-onset AEFI reported by AusVaxSafety participants following live attenuated herpes zoster vaccine by sex and underlying medical condition (final survey)*

	Males n (%)	Females n (%)	RR (95% CI) (females vs males)	No medical condition n (%)	Medical condition n (%)	RR (95% CI) (medical condition vs no condition)
Influenza-like Illness	10 (6.2)	22 (11.7)	1.88 (0.92 to 3.86)	17 (8.6)	15 (9.9)	1.16 (0.60 to 2.24)
Chickenpox-like rash	1 (0.6)	7 (3.7)	5.99 (0.75 to 48.2)	4 (2.0)	4 (2.6)	1.31 (0.33 to 5.16)
Hospitalisation †	1 (0.6)	1 (0.5)	0.86 (0.05 to 13.64)	2 (1.0)	0 (0.0)	NA

*Denominator includes Vaxtracker participants responding to a final opt-in survey by SMS or email sent 24 days following vaccination (M: 161, F: 188, total: 349). Of these, 151 had an underlying medical condition.

†Hospitalisation for allergic reaction (one following a dental procedure and one following consumption of shellfish).

AEFI, adverse events following immunisation; NA, not available; SMS, short message service.